DCTH: Rega marang dodolan Delcath
The investment potential of Delcath Systems, Inc. (DCTH) is based on management's determination to successfully commercialize innovative oncology systems. The price-to-sales ratio dynamics illustrate this trend, where the value of 6.70 captures the metric level. This growth is supported by the expansion of Hepzato into US clinics, featuring high-margin consumables and the exclusive right to exercise pricing power for the treatment of rare metastases.
Delcath (DCTH) - rincian metrik lan laporan keuangan
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Delcath Systems, Inc.|DCTH - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Delcath Corp|DCTH - Gunggung utang perusahaan|Rasio utang marang aset resik Delcath|DCTH - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Delcath Systems|Koefisien jangkoan perantara delcath.com
- rincian asil keuangan lan kelipatan valuasi:
DCTH - Penghasilan resik|Bathi resik sing dikarepake Delcath Systems, Inc.|DCTH - Rasio rega marang bathi|Kapitalisasi marang proyeksi bathi Delcath Systems Inc|DCTH - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Delcath|DCTH - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Delcath Systems|DCTH - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan delcath.com|DCTH - Wutah bathi saben saham ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Delcath Systems, Inc.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:delcath.com, DCTH
The business stability of Delcath Systems, Inc. (DCTH) depends on the commercialization pace of the HEPZATO KIT for hepatic chemical perfusion. By analyzing P/S ratio volatility, an investor compares market capitalization with actual sales volume, which allows for the identification of asset overvaluation or company undervaluation relative to its revenue, thereby determining the fair value of shares within the context of the biotechnology sector.
Karo sapa Delcath Systems, Inc. saingan
beigene.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S HALO (Halozyme)|Revolution Medicines Inc (RVMD) - Rega marang dodolan|AAPG - Rasio rega marang pendapatan|CGON: Rasio rega marang pendapatan|URGN: Multiplikator P/S|Kapitalisasi marang pendapatan bicara.com|PSNL (Personalis) - Multiplikator P/S|Multiplikator P/S Erasca Inc|Kapitalisasi marang pendapatan YMAB (YmAbs)|Kapitalisasi marang volume dodolan AURA|Multiplikator P/S CADL (Candel Therapeutics, Inc.)|Rasio kapitalisasi pasar marang pendapatan ARAY|SLS: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ACTU (Actuate Therapeutics Inc.)|Citius Oncology, Inc (CTOR) - Rasio rega marang pendapatan|HURA - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan TARA|Rega marang dodolan fatetherapeutics.com FATE|Rasio rega marang pendapatan Aadi Bioscience Inc (WHWK)|Koefisien rega marang pendapatan tscan.com|Champions Oncology, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan XBIT (XBiotech Inc)|CEL-SCI Corp - Multiplikator P/S|Rega marang dodolan ostherapies.com|Radiopharm Theranostics (RADX) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan Artiva Biotherapeutics|Rasio rega marang pendapatan Adlai Nortye Ltd|Veru Corporation (VERU) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan TPST (Tempest Therapeutics)|XLO (xiliotx.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S RENB (Renovaro)|Koefisien rega marang pendapatan Mural Oncology PLC (MURA)|KAPA - Rasio rega marang pendapatan|OKUR (OnKure Therapeutics Inc) - Rasio kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Kapitalisasi marang pendapatan Curis|Kapitalisasi marang pendapatan APLM|Tharimmune Inc (THAR) - Koefisien rega marang pendapatan|Multiplikator P/S ADVB|Genprex Inc - Rasio kapitalisasi marang pendapatan|Multiplikator P/S CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Kapitalisasi marang pendapatan|XBIO: Kapitalisasi marang pendapatan|Salarius Pharmaceuticals Inc - Kapitalisasi marang volume dodolan|PPBT: Multiplikator P/S|American Oncology Network, Inc. - Rasio kapitalisasi pasar marang pendapatan|BGNE (BeiGene, Ltd.) - Multiplikator P/S|Kapitalisasi marang pendapatan checkpointtx.com (CKPT)|Multiplikator P/S ELEV|Multiplikator P/S icadmed.com (ICAD)|Rasio rega marang pendapatan Ikena Oncology IKNA|NTBL: Rasio kapitalisasi marang pendapatan|Viracta - Multiplikator P/S|morphosys.com (MOR) - Kapitalisasi marang pendapatan|NAYA: Multiplikator P/S|Rega marang dodolan Ascentage Pharma Group International (AAPGV)
